Genzyme Corporation

Bing Wang

Bradford Hirth

John P Leonard

James W Lillie

Elyse Bourque

Hanlan Liu

Elina Makino

Paul Mason

Mary A Cromwell

Renato Sklerj

Thomas O'Shea

Fazeela Morshed

Lingyun Li

Kim Alving

Methods for quantifying the amount of drug present in a crosslinked hyaluronic acid-linker-peptide (xHA-L-P) prodrug composition are provided. Disclosed are steps of contacting a sample of the xHA-L-P prodrug formulation with a hyaluronoglucosidase to generate oligomeric hyaluronic acid-linker-peptide drug (oHA-L-P), contacting the oHA-L-P with a second enzyme to generate peptide digest products of the drug, and detecting the peptide digest products to determine the amount of the drug present in the xHA-L-P prodrug formulation.

Methods for quantifying drug concentration in a prodrug composition

The invention relates to inhibitors of glucosylceramide synthase (GCS) useful for the treatment metabolic diseases, such as lysosomal storage diseases, either alone or in combination with enzyme replacement therapy, and for the treatment of cancer.

Glucosylceramide synthase inhibitors

Growing community of inventors

Newton, MA, United States of America

Bing Wang